biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Berberine
Tier-CPublic-ready6/27/2026

Berberine

Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.

The 67.1 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the C tier remains conservative.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
101
Caution signal
Low
Context-specific research signal
67.1
Glucose and metabolic health markersCholesterol and triglyceridesBlood-Level or Deficiency Marker

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Glucose and metabolic health
12 studiesTier-B
Glucose and metabolic health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
65.6
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids
8 studiesTier-B
Cholesterol and triglycerides
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score
61.4
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Nutrient status and deficiency
2 studiesTier-C
Blood-Level or Deficiency Marker
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.

Evidence score
48.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Stress and mood
1 studiesTier-C
Stress Response and Sleep Changes
Some positive signal observedFelt benefit focusPatient-group study

These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.

Evidence score
42.1
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Immune and respiratory health
2 studiesTier-C
Immune and respiratory support
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
27.1
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood pressure and vascular health
3 studiesTier-C
Blood pressure and vascular health markers
Some positive signal observedResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
21.9
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Observed range in repeated studies

This range includes studies in specific patient groups. It is not a general dose or recommendation.

Lower observed study value
1000
mg/day
Higher observed study value
2000
mg/day
Only ranges repeated in human, oral, single-ingredient studies are shown.
Not personal dosing instructions, recommendations, or safety limits.

Key cautions to review

Standalone side-effect signals and combination cautions are listed separately.

Caution index
0.8
Caution band: Low
Caution signals
8
Side effects + combos + curated rules
Key precautions
No curated contraindication rule is available yet, but literature caution signals are shown below.
Standalone side effects, combination cautions, and positive combos are separated below.

Standalone side effects

gastrointestinal symptoms1 papers
Common side effects of berberine consumption include gastrointestinal symptoms such as constipation and diarrhea.human · systematic-review
Gastrointestinal side effects1 papers
Berberine treatment was associated with an increased incidence of gastrointestinal side effects compared to placebo.human · unknown
Adverse effect signal1 papers
Berberine treatment was reported to induce more gastrointestinal side effects compared to control groups.human · unknown
Gastrointestinal reactions1 papers
The review notes that only mild gastrointestinal reactions may occur in some patients taking berberine.human · systematic-review
Gastrointestinal adverse events1 papers
Berberine exhibits a favorable safety profile with only mild gastrointestinal adverse events reported.human · meta-analysis
Digestive system adverse events1 papers
Berberine treatment was associated with mild adverse events primarily affecting the digestive system.human · unknown
Diarrhea1 papers
Diarrhea was the most frequently reported adverse event in subjects treated with berberine ursodeoxycholate.human · rct
Adverse effect signal1 papers
The review reports that only mild gastrointestinal reactions may occur in some patients taking berberine.human · unknown

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 459
review

This review describes various methods mentioned in the literature so far with reference to the most important factors influencing berberine extraction, including thin layer chromatography, high performance liquid Chromatography, and mass spectrometry.

Key Evidence #2
Public scholarly dataCitation signal: 388
observational

This supramolecular self-assembly strategy can be applied to construct other nanoscale antibacterial drugs and thus provides weapons for the development of self-delivering drugs in bacterial infection treatment.

Key Evidence #3
Public scholarly dataCitation signal: 387
review

A timely overview of the pharmacological properties and therapeutic application of BBR in CVMD is provided, and recent pharmacological advances which validate BBR as a promising lead drug against CVMD are underlined.

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 315
observational

It is demonstrated in a randomized controlled trial that effects of berberine, a plant alkaloid known to lower blood glucose, may be explained by the inhibition of Ruminococcus bromii mediated biotransformation of the bile acid deoxycholic acid.

Public scholarly dataCitation signal: 310
review

The purpose of this review is to provide a summary concerning the clinical trials conducted on berberine to improve the clinical application of this nutraceutical in different diseases.

Public scholarly dataCitation signal: 285
review

Examples in the pharmacokinetics field, obesity, hyperlipidaemia, diabetes, cancer, inflammatory disease conditions, etc are used to show the link between the gut microbiota and the polypharmacology of berberine.

Berberine
arrow_backBack to list